EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice

Ronaldo José Pineda-Wieselberg iD, Andressa Heimbecher Soares, Thiago Fraga Napoli iD, Nilza Maria Scalissi, João Eduardo Nunes Salles

Nutrients · 30.04.2026 · 18 (9) · 1419

DOI: 10.3390/nu18091419 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Nutrients, online erschienen am 30.04.2026. Verfasst von Ronaldo José Pineda-Wieselberg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Endocrinology, Santa Casa de Misericórdia de São Paulo, São Paulo 01221-020, Brazil. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents, Feeding Behavior, Precision Medicine. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Obesity is a heterogeneous chronic disease in which eating behavior phenotypes may influence treatment response. Yet, anti-obesity medication (AOM) selection is still largely guided by anthropometric and metabolic parameters, with limited use of behavioral phenotyping in routine practice. We evaluated whether multidimensional eating behavior changes, measured by the Brazilian Eating Behavior Phenotype Scale (Escala de Fenótipos do Comportamento Alimentar, EFCA), differ across commonly used AOMs in a real-world cohort.

Methods

We conducted a retrospective, observational, real-world study in obesity outpatient care settings in São Paulo, Brazil. Adults with obesity (18–65 years) treated with a single principal AOM for 6 months and paired baseline/6-month follow-up EFCA and anthropometric data were included. Analyses focused on early responders (≥5% total body weight loss at 3 months). Five AOM groups available in Brazil were analyzed: semaglutide (oral or subcutaneous), naltrexone/bupropion, sibutramine, topiramate, and tirzepatide. Outcomes included percent weight loss, EFCA total score, and five EFCA subscales (hedonic, emotional, compulsive, hyperphagic, disorganized). Within-medication behavioral changes were assessed using paired tests and standardized effect sizes (Cohen’s dz, 95% CI), summarized in heatmap form.

Results

The analytical cohort comprised 66 early responders with paired EFCA assessments at baseline and 6 months. EFCA profiling revealed distinct behavioral response fingerprints across AOMs. Effect size mapping showed predominantly large behavioral effects (many dz ≥ 0.8) in hedonic, emotional, hyperphagic, and compulsive domains. Strongest signals included emotional eating reductions with naltrexone/bupropion (dz 2.04), tirzepatide (dz 1.77), semaglutide (dz 1.52), and topiramate (dz 1.54); hedonic reductions with tirzepatide (dz 2.06), semaglutide (dz 1.55), and naltrexone/bupropion (dz 1.52); hyperphagic reductions with tirzepatide (dz 1.50) and semaglutide (dz 1.34); and compulsive reductions with topiramate (dz 1.41) and consistent effects across tirzepatide, semaglutide, and sibutramine (≈dz 0.95–0.96). Disorganized eating showed heterogeneous/attenuated responsiveness, from near-null with tirzepatide (dz 0.03) to large but imprecise effects in smaller groups (e.g., topiramate dz 1.24, wide CI).

Conclusions

In this responder-enriched real-world cohort, AOMs showed distinct and reproducible EFCA behavioral signatures, supporting a clinically actionable phenotype-informed framework to prioritize, sequence, and monitor obesity pharmacotherapy beyond nonspecific weight reduction, while highlighting disorganization as a potential target for adjunctive behavioral strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ObesityAnti-Obesity AgentsFeeding BehaviorPrecision MedicineHumansSemaglutideAdultMiddle AgedFemaleMalePhenotypeRetrospective StudiesTirzepatideTopiramateWeight LossAdolescentBupropionBrazilYoung AdultCyclobutanesNaltrexoneAgedTreatment OutcomeFructose

Stichwörter der Autor:innen

anti-obesity medicationsbehavioral scalesobesityobesity phenotypesprecision medicine

Substanzen

SemaglutideAnti-Obesity AgentsTirzepatideTopiramateBupropionsibutramineCyclobutanesNaltrexoneFructose

Autor:innen und Institutionen

  • Discipline of Endocrinology, Santa Casa de Misericórdia de São Paulo, São Paulo 01221-020, Brazil.

ORCID-Profile: Ronaldo José Pineda-Wieselberg, Thiago Fraga Napoli

Zitieren

APA

Pineda-Wieselberg, R. J., Soares, A. H., Napoli, T. F., Scalissi, N. M., & Salles, J. E. N. (2026). Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice. Nutrients, 18(9), 1419. https://doi.org/10.3390/nu18091419

Vancouver

Pineda-Wieselberg RJ, Soares AH, Napoli TF, Scalissi NM, Salles JEN. Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice. Nutrients. 2026;18(9):1419. doi:10.3390/nu18091419

BibTeX
@article{PinedaWieselberg2026,
  author = {Pineda-Wieselberg, Ronaldo José and Soares, Andressa Heimbecher and Napoli, Thiago Fraga and Scalissi, Nilza Maria and Salles, João Eduardo Nunes},
  title = {Toward Precision Obesity Pharmacotherapy: Using the Eating Behavior Phenotype Scale (EFCA) in Real-World Clinical Practice},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {9},
  pages = {1419},
  doi = {10.3390/nu18091419}
}
Kostenlos starten →